|Study Description:||The goal of this clinical research study is to learn about the safety of giving |
Idelalisib (also known as CAL-101) in combination with rituximab, ofatumumab,
bendamustine, fludarabine, chlorambucil, everolimus, bortezomib, and
lenalidomide to patients with NHL, MCL, or CLL. Researchers also want to learn
if this study drug combination can help to control the disease.